1. Home
  2. RLMD vs EH Comparison

RLMD vs EH Comparison

Compare RLMD & EH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$5.93

Market Cap

661.9M

Sector

Health Care

ML Signal

HOLD

Logo EHang Holdings Limited ADS

EH

EHang Holdings Limited ADS

HOLD

Current Price

$7.86

Market Cap

679.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLMD
EH
Founded
2004
2014
Country
United States
China
Employees
17
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
661.9M
679.5M
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
RLMD
EH
Price
$5.93
$7.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$12.40
$22.47
AVG Volume (30 Days)
925.0K
715.6K
Earning Date
05-08-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
45.28
N/A
EPS
N/A
N/A
Revenue
$13,070.00
N/A
Revenue This Year
N/A
$33.23
Revenue Next Year
N/A
$73.83
P/E Ratio
N/A
N/A
Revenue Growth
154.83
N/A
52 Week Low
$0.52
$8.95
52 Week High
$8.00
$20.44

Technical Indicators

Market Signals
Indicator
RLMD
EH
Relative Strength Index (RSI) 32.00 29.95
Support Level $5.68 N/A
Resistance Level $7.46 $10.68
Average True Range (ATR) 0.41 0.55
MACD -0.14 -0.09
Stochastic Oscillator 5.11 3.62

Price Performance

Historical Comparison
RLMD
EH

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

About EH EHang Holdings Limited ADS

EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

Share on Social Networks: